Aripiprazole in the treatment of patients with alcohol dependence: A double-blind, comparison trial vs. Naltrexone

Journal of Psychopharmacology

Volumn 23, Issue 2, 2009, Pages 123-129

  Martinotti, G ^a,c   Di Nicola, M ^a   Di Giannantonio, M ^b   Janiri, L ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Clinica Villa Maria Pia   (Italy)

Author keywords

Alcohol dependence; Craving; Dopamine; Dual diagnosis; Partial agonists

Indexed keywords

ARIPIPRAZOLE; NALTREXONE; NARCOTIC ANTAGONIST; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AKATHISIA; ALCOHOL ABSTINENCE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYMPTOM; SYMPTOM CHECKLIST 90; VISUAL ANALOG SCALE; VOMITING; WITHDRAWAL SYNDROME; COMPARATIVE STUDY; DRINKING BEHAVIOR; RECURRENT DISEASE;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERAZINES; QUINOLONES; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 67651173275     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089596     Document Type: Article

References (50)

1. Addolorato G, Abenavoli L, Leggio L, Gasbarrini G, (2005) How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: a review. Neuropsychobiology 51: 59 - 66.
2. Addolorato G, Leggio L, Agabio R, Colombo G, Gasbarrini G, (2006) Baclofen: a new drug for the treatment of alcohol dependence. Int J Clin Pract 60: 1003 - 1008.
3. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson LH, Stolt G, Willander A, (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27: 1142 - 1149.
4. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF,. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 25: 363 - 366.
5. Bono G, Balducci C, Richelmi P, Koob GF, Pulvirenti L, (1996). Dopamine partial receptor agonists reduce ethanol intake in the rat. Eur J Pharmacol 296: 233 - 238.
6. Borg V, (1983) Bromocriptine in the prevention of alcohol abuse. Acta Psychiatr Scand 68: 100 - 110.
7. Caine SB, Koob GF, Parsons LH, Everitt BJ, Schwartz JC, Sokoloff P, (1997) D3 receptor test in vitro predicts decreased cocaine self-administration in rats. Neuroreport 8: 2373 - 2377.
8. Carlsson C, Gullberg B, (1978) A double blind study with melperone and placebo in the treatment of chronic alcoholics. Int J Clin Pharmacol Biopharm 16: 331 - 332.
9. Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M, (2006) Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand 113: 148 - 153.
10. Cloninger CR, Svrakic DM, Przybeck TR, (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50: 975 - 990.
11. De Sousa A, (2004) A 1-year pragmatic trial of naltrexone vs. disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 39: 528 - 531.
12. Derogatis LR, Lipman RS, Covi L, (1976) SCL-90: An outpatient psychiatric rating scale: Preliminary report. In: W Guy, (ed) ECDEU Assessment Manual for Pychopharmacology. Revised. DHEW Publication No. (ADM) 76-338. Washington, DC: US Department of Health, Education, and Welfare ; pp. 218 - 222.
13. Dongier M, Vachon L, Schwartz G, (1991) Bromocriptine in the treatment of alcohol dependence. Alcohol Clin Exp Res 15: 970 - 977.
14. Eiler K, Schaefer MR, Salstrom D, Lowery R, (1995) Double-blind comparison of bromocriptine and placebo in cocaine withdrawal. Am J Drug Alcohol Abuse 21: 65 - 79.
15. Guy W, (1976) ECDEU Assessment Manual for Pychopharmacology. Washington, DC: US Department of Health, Education, and Welfare.
16. Heinz A, Siessmeier T, Wrase J, Buchholz HG, Grunder G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rosch F, Mann K, Bartenstein P, (2005) Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 162: 1515 - 1520.
17. Hung GC, Chen YY, (2007) Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient. Pharmacopsychiatry 40: 83 - 84.
18. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D, Swift R, (2006) The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31: 1310 - 1317.
19. Ingman K, Kupila J, Hyytia P, Korpi ER, (2006) Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol 41: 391 - 398.
20. Janiri L, Calvosa F, Dario T, Pozzi G, Ruggeri A, Addolorato G, Di Giannantonio M, De Risio S, (2004) The Italian version of the Obsessive-Compulsive Drinking Scale: validation, comparison with the other versions, and difference between type 1- and type 2-like alcoholics. Drug Alcohol Depend 74: 187 - 195.
21. Janiri L, Martinotti G, Di Nicola M, (2007) Aripiprazole for relapse prevention and craving in alcohol dependent subjects: results from a pilot study. J Clin Psychopharmacol (in press).
22. Johnson BA, (2000) Serotonergic agents and alcoholism treatment, rebirth of the subtype concept - an hypothesis. Alcohol Clin Exp Res 24: 1597 - 1801.
23. Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O'Brien CP, (2007) A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 27: 344 - 351.
24. Kenna G, Swift R, (2004) Pharmacotherapies for alcohol dependence. US Pharm 93 - 101.
25. Kenna GA, (2003) Rationale for use of aripiprazole for alcohol dependence treatment. Drugs Future 28: 1227 - 1235.
26. Kenna GA, (2005) Pharmacotherapy of alcohol dependence: targeting a complex disorder. Drug Discov Today: The Strateg 2: 71 - 78.
27. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ, (1994) Buspirone treatment of anxious alcoholics. A placebo-controlled trial. Arch Gen Psychiatry 51: 720 - 731.
28. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA,. Veterans Affairs Naltrexone Cooperative Study 425 Group (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734 - 1739.
29. Lejoyeux M, Solomon J, Ades J, (1998) Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 33: 563 - 575.
30. Martinotti G, Di Nicola M, Janiri L, (2007) Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 33: 393 - 401.
31. Martinotti G, Di Nicola M, Reina D, Andreoli S, Foc F, Cunnif A, Bria P, Janiri L, (2007) Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse (in press).
32. Mottola CA, (1993) Measurement strategies: the visual analogue scale. Decubitus 6: 56 - 58.
33. Maxwell S, Shinderman MS, (2000) Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis 19: 61 - 69.
34. Naranjo CA, Dongier M, Bremner KE, (1997) Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 92: 969 - 978.
35. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J,. Rother, Wk, Loew, TH, Kaplan, P (2006) Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 163: 833 - 838.
36. Noble E, (1996). The gene that rewards alcoholism. Sci Am Sci Med 3: 56 - 61.
37. Piercy KT, Bjork AK, Myers RD, (1996) The mixed 5-HT 1A/2A receptor drug FG5938 suppresses alcohol drinking while enhancing feeding in P rats. Alcohol 13: 521 - 527.
38. Robinson TE, Berridge KC, (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 18: 247 - 291.
39. Romach MK, Sellers EM, Somer GR, Landry M, Cunningham GM, Jovey RD, McKay C, Boislard J, Mercier C, Pepin JM, Perreault J, Lemire E, Baker RP, Campbell W, Ryan D, (2002) Naltrexone in the treatment of alcohol dependence: a Canadian trial. Can J Clin Pharmacol 9: 130 - 136.
40. Rosenbaum JF, Fredman SJ, (1999) Pramipexole treatment for cocaine cravings. Am J Psychiatry 156: 1834.
41. Rothman RB, Blough BE, Baumann MH, (2007) Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J 9: E1 - E10.
42. Singh GK, Kalmus GW, Bjork AK, Myers RD, (1993) Alcohol drinking in rats is attenuated by the mixed 5-HT1 agonist/5-HT2 antagonist FG 5893. Alcohol 10: 243 - 248.
43. Shaw GK, Majumdar SK, Waller S, MacGarvie J, Dunn G, (1987) Tiapride in the long-term management of alcoholics of anxious or depressive temperament. Br J Psychiatry 150: 164 - 168.
44. Srisurapanont M, Jarusuraisin N, (2005) Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8: 267 - 280.
45. Stahl SM, (2001) Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 62: 923 - 924.
46. Stoops WW, Lile JA, Glaser PE, Rush CR, (2006) A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 13.
47. Sullivan JT, Sykora K, Schneideman J, (1989) Assessment of alcohol withdrawal: the revised clinical Institute Withdrawal Assessment for Alcohol scale (CIWA Ar). Br J Addict 84: 1353 - 1357.
48. Valicenti-McDermott MR, Demb H, (2006) Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 16: 549 - 560.
49. Walter H, Ramskogler K, Semler B, Lesch OM, Platz W, (2001) Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci 8: 83 - 88. Review.
50. Warsi M, Sattar SP, Bhatia SC, Petty F, (2005) Aripiprazole reduces alcohol use. Can J Psychiatry 50: 244.